1-3 of 3
gemcitabine
Close
Sort by
Journal Articles

Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma

Clinical Trials & Observations
Armando Santoro, Rita Mazza, Alessandro Pulsoni, Alessandro Re, Maurizio Bonfichi, Vittorio Ruggero Zilioli, Manuela Zanni, Francesco Merli, Antonella Anastasia, Stefano Luminari, Giorgia Annechini, Manuel Gotti, Annalisa Peli, Anna Marina Liberati, Nicola Di Renzo, Luca Castagna, Laura Giordano, Francesca Ricci, Carmelo Carlo-Stella
Journal: Blood Advances
Blood Adv (2020) 4 (1): 136–140.
https://doi.org/10.1182/bloodadvances.2019000984
Published: 2020
Includes: Supplemental data
Journal Articles

The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma

Kyle Runckel, Matthew J. Barth, Cory Mavis, Juan J. Gu, Francisco J. Hernandez-Ilizaliturri
Journal: Blood Advances
Blood Adv (2018) 2 (23): 3516–3525.
https://doi.org/10.1182/bloodadvances.2018018168
Published: 2018
Includes: Supplemental data
Journal Articles

Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase

Sarah E. Fordham, Helen J. Blair, Claire J. Elstob, Ruth Plummer, Yvette Drew, Nicola J. Curtin, Olaf Heidenreich, Deepali Pal, David Jamieson, Catherine Park, John Pollard, Scott Fields, Paul Milne, Graham H. Jackson, Helen J. Marr, Tobias Menne, Gail L. Jones, James M. Allan
Journal: Blood Advances
Blood Adv (2018) 2 (10): 1157–1169.
https://doi.org/10.1182/bloodadvances.2017015214
Published: 2018
Includes: Supplemental data